Clay Siegall’s Contribution To Cancer Research

Seattle Genetics’ Clay B. Siegall had a personal experience with cancer. In a recent interview with Ideamensch, the executive leader revealed that when he was 19 years old, the doctor told his family that their father had been diagnosed with cancer. His dad battled with the disease for five years. This experience enabled Clay Siegall to see the limited tools that were at the disposal of oncologists. He decided to work towards changing this situation by studying genetics. Clay believed that although he had lost his father, other families with cancer patients did not have to go through the same experience. Clay earned his doctorate degree in genetics from the George Washington University. His passion for research saw him work for Bristol-Myers Squibb.

Dr. Siegall advises young entrepreneurs to gain much knowledge in different fields as they grow up. He notes that most entrepreneurs in their 20s think that they know everything. However, they know very little. As one grows, he or she learns the necessary skills to run a successful enterprise. Reading widely and interacting with smart people in various fields helps one to gain more knowledge.

Clay posits that partnering with different people and organizations has helped him to grow his business. Dr. Siegall contends that by collaborating with other industry leaders and innovators in development of viable cancer therapies has enabled Seattle Genetics to advance its ADC technology. To this end, the corporation has been able to invest its resources wisely. The company has benefited from Siegall’s transformative leadership skills.

About Clay B. Siegall

Clay B. Siegall is the president, chief executive officer, and chairman of Seattle Genetics. The scientist co-founded the biotech company in 1998. Under his leadership, the company’s shares have tripled in the last five years, an indicator of investor confidence in the corporation’s management. Clay was heavily involved in ensuring that the company’s cancer drug, ADCETRIS has been approved by the FDA. Through partnerships with different companies, the drug has been marketed in over 65 countries.

Siegall has played an integral role in ensuring that Seattle Genetics has adequate funds to run its operations. In the last 20 years, he has helped the company to raise over $1.2 billion. Some of the money was raised through the company’s initial public offering in 2001. He has also received money through both public and private financing.